Loading…
Loading…
what would you say are the leading indicators of a rebound in aesthetics, I'm just trying to assess what green shoots perhaps you may be seeing
What would you say are the main elements that you'd want to see in reform
you guys called out the partial impairment today in the press release. Just want to get your perspective as to what the drivers are for the remaining value
is it fair to say that you think '25 could be the trough or have already seen a trough in terms of the growth rate
post ADA, were there any changes that you guys made to Phase III, just thinking increased entry criteria or maybe pace of titration just to optimize discontinuations?
the OUS contribution, I think, is going to be much bigger when you compare to Descovy or Truvada and PrEP
what's the gating factor for selecting the best phase three combo? And related to that, you know, while you haven't seen resistance with len
do you guys view all the different Len treatment options that you detailed on Slide 20 as eventually replacing Biktarvy
is the ultimate goal to have meaningfully more indications than Tirzepatide just given the oral convenience?
Can you guys speak to trends on duration of therapy or maybe real-world safety tolerability
maybe talk about the selection of the indications that you just announced from a mechanism perspective
can you talk about Merck's mitigating strategies as an offset whether it's a new CapEx cycle
is there an inventory threshold that you need to see to start shipping again
what incentives would you want to see in tariff negotiations that would maybe tip the balance for Pfizer Inc. to, you know, to increase manufacturing investments here in the US?
what would you say ranks as a higher priority just with respect to how you tier, you know, what would be multiple BD options
for the COVID franchise, you guys talked about stabilizing revenue for this year. Maybe just give us some level of conviction
just want to get a sense from you guys for the appetite for growing out the number of TAs